ABBV Latest Quotes, Charts & Stock Information

Home » ABBV

Latest Insights on ABBV

The Real Question for the $63 Billion AbbVie-Allergan Acquisition

by Joseph Hargett June 25, 2019 Great Stuff

I know my brain doesn’t work quite right. I wouldn’t be writing Great Stuff if it did. Today, I’m left with a burning question on AbbVie’s $63 billion cash and stock acquisition of Allergan. It’s not about the viability of the combined company. Both AbbVie Inc. (NYSE: ABBV) and Allergan PLC (NYSE: AGN) face serious […]

This Biotech Billionaire Loves This Risky Stock

by Brian Christopher April 11, 2018 Technology, Trending

There is a chance you will lose money if you buy today’s stock. But if you’re willing to take on a little risk, I have an opportunity for you that could be very profitable.

Newsletter Sign Up

CS Care Video

MEET OUR EXPERTS

Andrew Prince
Research Analyst
Banyan Hill
John Wilkinson
Director of VIP Services
Michael Carr
Editor of Precision Profits and Apex Alert
Ian King
Editor of Strategic Fortunes and three elite services
Adam O'Dell
Chief Investment Strategist of Money & Markets
Aaron James
CEO of Banyan Hill
Amber Lancaster
Director of Investment Research
Charles Mizrahi
Editor of Alpha Investor

WHAT READERS ARE SAYING..

"You told me to ignore the noise on Wall Street. And thanks to you, I started towards the end of 2016 with $200,000 in my account and I recently put in an extra $100,000. [As of February 2019] My account is worth $500,788! I would’ve missed out if I followed conventional wisdom."

- Helen C.

“I started with $215,000 in Nov. 2018, It is now over 800,000. So very happy with Banyan Hill Publishing.”

- Larry K.

“I'm very Happy with your services. I hope you don't plan to retire any time soon! My retirement portfolio depends on your expert guidance. Keep up the great work! Thanks.”

- Randy